French pharma major Sanofi (Euronext: SAN) and US partner Regeneron Pharmaceuticals (Nasdaq: REGN) announced late Tuesday that the European Commission (EC) has approved a new indication for Dupixent (dupilumab) in asthma.
Sanofi’s shares were down 0.63% at 75.75 euros in late morning trading in Paris today, while Regeneron closed down 6.34% at $322.40 on Tuesday.
Dupixent is now approved in the European Union for use in adults and adolescents 12 years and older as an add-on maintenance treatment for severe asthma with type 2 inflammation characterized by raised blood eosinophils and/or raised fractional exhaled nitric oxide (FeNO), who are inadequately controlled with high dose inhaled corticosteroid (ICS) plus another medicinal product for maintenance treatment.
People with severe asthma often have inadequately controlled, persistent symptoms that may make them suitable for treatment with a biologic therapy. These patients live with coughing, wheezing and difficulty breathing, and are at risk of severe asthma attacks that may require emergency room visits or hospitalizations.
